Security readout for executives and security teams
Plain-English summary
Darktrace’s Android mobile app before 6.0.15 could let disabled or low-privilege users trigger Antigena traffic block and unblock actions. In the worst case, those actions could disrupt ingress or egress traffic across infrastructure where Darktrace agents are deployed.
Executive priority
Prioritize remediation if Darktrace Antigena can affect production traffic. The risk is operational disruption rather than confirmed active exploitation, so treat it as urgent for exposed environments.
Technical view
CVE-2023-29656 is an improper authorization issue in the Darktrace Android mobile app prior to 6.0.15. The published record says unauthorized users could control Antigena actions. No CVSS score, CWE, affected CPEs, or detailed vendor mitigation are included in the provided sources.
Likely exposure
Organizations using Darktrace with Android mobile app versions earlier than 6.0.15 are the relevant exposure group. Risk is higher where Antigena actions can affect broad network traffic.
Exploitation context
The provided sources do not show CISA KEV listing, public active exploitation, or exploit maturity. The impact claim is serious, but operational details and prerequisites are incomplete.
Researcher notes
The CVE record is sparse: no CVSS, CWE, CPE, exploit status, or detailed advisory text is available in the supplied bundle. Analysis relies mainly on the CVE description and version boundary.
Mitigation direction
- Update Darktrace Android mobile app to version 6.0.15 or later.
- Check Darktrace guidance for any additional server-side or policy remediation.
- Restrict mobile app access for users who do not require Antigena control.
- Review disabled and low-privilege accounts for lingering access or sessions.
- Monitor for unexpected Antigena block or unblock actions.
Validation and detection
- Inventory deployed Darktrace Android mobile app versions.
- Confirm no users run Android app versions earlier than 6.0.15.
- Review Darktrace audit logs for unexpected Antigena actions.
- Verify disabled users cannot access mobile app functionality.
- Verify low-privilege roles cannot control Antigena actions.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2023-29656 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS and timeline data
No CVSS vectors or timeline events were available in the normalized CVE source material.
Source materials
- CVE List V5 sourceCVE List V5
- https://darktrace.com/CVE reference
- https://ramihub.github.io/CVE reference
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.